Paradigm Biocapital Advisors LP
- SEC CIK
- 0001855655
- Latest filing
- Aug 14, 2026
Holdings in Q3 2022
Holdings as of Sep 30, 2022, filed Nov 14, 2022. Long positions only; changes compare share counts with Q2 2022.
- Positions
- 27
- +4 vs. Q2 2022
- Portfolio value
- $710.1M
- +$208.6M (+41.6%) vs. Q2 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| GBTGlobal Blood Therapeutics, Inc. | COM | 1,175,879 | $80.1M | 11.3% | −269,687−18.7% | Reduced | History |
| MRTXMirati Therapeutics, Inc. | COM | 850,385 | $59.4M | 8.4% | +190,417+28.9% | Added | History |
| INCYIncyte Corp | COM | 773,082 | $51.5M | 7.3% | +217,039+39.0% | Added | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 497,347 | $51.4M | 7.2% | +65,177+15.1% | Added | History |
| LEGNLegend Biotech Corp | SPONSORED ADS | 1,076,591 | $43.9M | 6.2% | +97,995+10.0% | Added | History |
| BIIBBiogen Inc. | COM | 154,605 | $41.3M | 5.8% | +154,605 | New | History |
| IMCRImmunocore Holdings plc | ADS | 773,079 | $36.3M | 5.1% | +105,662+15.8% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,636,211 | $33.6M | 4.7% | +329,642+25.2% | Added | History |
| ARGXArgenx SE | SPONSORED ADR | 90,297 | $31.9M | 4.5% | +1,481+1.7% | Added | History |
| UTHRUnited Therapeutics Corp | COM | 140,561 | $29.4M | 4.1% | −22,505−13.8% | Reduced | History |
| AKROAkero Therapeutics, Inc. | COM | 833,265 | $28.4M | 4.0% | +833,265 | New | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 1,158,686 | $27.0M | 3.8% | +110,170+10.5% | Added | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 1,085,142 | $26.1M | 3.7% | +208,986+23.9% | Added | History |
| AXSMAxsome Therapeutics, Inc. | COM | 520,080 | $23.2M | 3.3% | +520,080 | New | History |
| HZNPHorizon Therapeutics Public Ltd Co | SHS | 351,405 | $21.7M | 3.1% | +351,405 | New | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 2,214,722 | $15.9M | 2.2% | +1,387,943+167.9% | Added | History |
| PRTAProthena Corp Public Ltd Co | SHS | 235,826 | $14.3M | 2.0% | +235,826 | New | History |
| ARVNArvinas, Inc. | COM | 283,777 | $12.6M | 1.8% | −233,629−45.2% | Reduced | History |
| ESPREsperion Therapeutics, Inc. | COM | 1,719,831 | $11.5M | 1.6% | +311,781+22.1% | Added | History |
| MRUSMerus N.V. | COM | 564,214 | $11.3M | 1.6% | +111,970+24.8% | Added | History |
| GTHXG1 Therapeutics, Inc. | COM | 884,574 | $11.0M | 1.6% | +884,574 | New | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 519,256 | $10.2M | 1.4% | +519,256 | New | History |
| OYSTOyster Point Pharma, Inc. | COM | 1,648,316 | $9.26M | 1.3% | +314,986+23.6% | Added | History |
| TGTXTG Therapeutics, Inc. | COM | 1,505,479 | $8.91M | 1.3% | −459,230−23.4% | Reduced | History |
| PSTXPoseida Therapeutics, Inc. | COM | 2,070,108 | $7.31M | 1.0% | +2,070,108 | New | History |
| VORVor Biopharma Inc. | COM | 1,703,645 | $6.78M | 1.0% | +399,345+30.6% | Added | History |
| MISTMilestone Pharmaceuticals Inc. | COM | 634,211 | $5.83M | 0.8% | +634,211 | New | History |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| BIIBBiogen Inc. | COM | – | $40.0M |
Sold out since Q2 2022 (5)
Positions held at the end of Q2 2022 that are gone from this filing.
| Security | Class | Shares in Q2 2022 | Value in Q2 2022 | % of portfolio in Q2 2022 | History |
|---|---|---|---|---|---|
| SRRASierra Oncology, Inc. | COM NEW | 801,314 | $44.1M | 8.8% | History |
| ENTAEnanta Pharmaceuticals Inc | COM | 148,216 | $7.01M | 1.4% | History |
| Gracell Biotechnologies Inc38406L103 | SPONSORED ADS | 783,445 | $4.31M | 0.9% | – |
| LQDALiquidia Corp | COM NEW | 850,961 | $3.71M | 0.7% | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 73,149 | $552.0K | 0.1% | History |